KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Income towards Parent Company (2016 - 2026)

Abbott Laboratories' Income towards Parent Company history spans 18 years, with the latest figure at $1.1 billion for Q1 2026.

  • On a quarterly basis, Income towards Parent Company fell 18.72% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $6.3 billion, a 53.52% decrease, with the full-year FY2025 number at $6.5 billion, down 51.32% from a year prior.
  • Income towards Parent Company hit $1.1 billion in Q1 2026 for Abbott Laboratories, down from $1.8 billion in the prior quarter.
  • Over the last five years, Income towards Parent Company for ABT hit a ceiling of $9.2 billion in Q4 2024 and a floor of $1.0 billion in Q4 2022.
  • Historically, Income towards Parent Company has averaged $2.0 billion across 5 years, with a median of $1.4 billion in 2023.
  • Biggest five-year swings in Income towards Parent Company: soared 478.98% in 2024 and later crashed 80.76% in 2025.
  • Tracing ABT's Income towards Parent Company over 5 years: stood at $1.0 billion in 2022, then surged by 54.31% to $1.6 billion in 2023, then soared by 478.98% to $9.2 billion in 2024, then crashed by 80.76% to $1.8 billion in 2025, then crashed by 39.36% to $1.1 billion in 2026.
  • Business Quant data shows Income towards Parent Company for ABT at $1.1 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.6 billion in Q3 2025.